This document lists 30 publications and 6 presentations by Dr. Lin Wang related to head and neck cancer research. The publications cover topics such as increased expression of HER2/HER3 in HPV-positive head and neck squamous cell carcinoma, differential significance of subcellular MDM2 expression in HNSCC, targeting of STAT3 to abrogate EGFR inhibitor resistance, and the mutational landscape of head and neck squamous cell carcinoma. The presentations were given at American Society of Nephrology conferences between 2001-2006 on topics including the role of MKK3-p38 MAPK pathways in mediating TGF-β1 signaling.

1. SELECTED PUBLICATIONS
1. Wang L, Pollock N, Wallweber J, Gooding WE, Huang WD, Winslow J,.
Grandis JR. Increased expression of HER2 and HER3 in HPV-positive
HNSCC using a novel proximity-based assay. Clin Cancer Res.
(Submitted)
2. Wang L, Chiosea S, Grandis JR. Differential pathological significance of
subcellular MDM2 expression in head and neck squamous cell carcinoma
(HNSCC). (Manuscript)
3. Srivastava RM, Trivedi S, Concha-Benavente F, Jie HB, Wang L, Seethala
RR, Branstetter BF, Ferrone S, Ferris RL. STAT1 Induced HLA class I
Upregulation Enhances Immunogenicity and Clinical Response to anti-EGFR
mAb Cetuximab Therapy in HNC Patients. Cancer Immunol Res. 2015 May
13. pii: canimm.0053.2015. [Epub ahead of print]
4. Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis
JR. Challenges in EGFRvIII detection in head and neck squamous cell
carcinoma. PLoS One. 2015 Feb 6;10(2):e0117781.
5. Nakajima EC, Laymon C, Oborski M, Hou W, Wang L, Grandis JR, Ferris RL,
Mountz JM, Van Houten B. Quantifying Metabolic Heterogeneity in Head and
Neck Tumors in Real Time: 2-DG Uptake Is Highest in Hypoxic Tumor Regions.
PLoS One. 2014 Aug 15;9(8):e102452. doi: 10.1371/journal.pone.0102452.
eCollection 2014.
6. Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR,
Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness
BA, Forastiere AA. Phase II study of cetuximab in combination with cisplatin
and radiation in unresectable, locally advanced head and neck squamous cell
carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res.
2014 Oct 1;20(19):5041-51
7. Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S,
Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A,
Wirth L, Nikiforova MN, Siegfried JM, Grandis JR. Erlotinib, erlotinib-sulindac
versus placebo: a randomized, double-blind, placebo-controlled window trial in
operable head and neck cancer. Clin Cancer Res. 2014 Jun 15;20(12):3289-98.

2. 8. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su
AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ,
Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK,
Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY. EGFR phosphorylation of
DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin
Invest. 2014 Sep 2; 124 (9):3741-5.

3. 9. Vaezi AE, Bepler G, Bhagwat NR, Malysa A, Rubatt JM, Chen W, Hood
BL, Conrads TP, Wang L, Kemp CE, Niedernhofer LJ. Choline phosphate
cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1
antibody 8F1 with biomarker value in patients with lung and head and
neck squamous cell carcinomas. Cancer. 2014 June 15; 120 (12): 1898-
1907.
10. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L,
Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du
Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE,
Grandis JR. Frequent mutation of receptor protein tyrosine phosphatases
provides a mechanism for STAT3 hyperactivation in head and neck
cancer; Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1114-9.
11.Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J,
Grandis JR. Systemic administration of a cyclic signal transducer and
activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor
growth without inducing toxicological effects. Mol Med. 2014 Mar
18;20:46-56
12.Troy JD, Weissfeld JL, Youk AO, Thomas S, Wang L, Grandis JR.
Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor
Angiogenesis in HPV-Positive and HPV-Negative Head and Neck
Squamous Cell Carcinoma. Head Neck Pathol. Head Neck Pathol. 2013
Dec;7(4):344-55
13. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y,
Zhang Q, Du Y, Gilbert B, Freilino M, Sauerwein S, Peyser N, Xiao D,
Diergaarde B, Wang L, Chiosea S, Seethala RR, Johnson JT, Kim S,
Duvvuri U, Ferris RL, Romkes M, Nukui T, Ng PK, Garraway LA,
Hammerman P, Mills GB, Grandis JR. Frequent mutation of the PI3K
pathway in head and neck cancer defines predictive biomarkers. Cancer
Discov. 2013 Jul;3(7):761-9.
14. Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L,
Seethala RR, Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits
pSTAT1-mediated APM component expression, T-cell attracting
chemokine secretion, and CTL recognition in head and neck cancer cells.
Clin Cancer Res. 2013 Feb 15;19(4):798-808.

4. 15. Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC,
Thomas SM, Grandis JR. Targeting TORC1/2 enhances sensitivity to
EGFR inhibitors in head and neck cancer preclinical models. Neoplasia.
2012 Nov;14(11):1005-14
16. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J,
Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting Stat3
abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res. 2012 Sep
15;18(18):4986-96. doi: 10.1158/1078-0432.CCR-12-0792.
17. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U,
Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S,
Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X,
Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-human trial of a
STAT3 decoy oligonucleotide in head and neck tumors: implications for
cancer therapy. Cancer Discov. 2012 Aug;2(8):694-705. doi:
10.1158/2159-8290.
18. Wheeler SE, Siwak DR, Chai RL, Lavalle CR, Seethala RR, Wang L,
Cieply KM, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis
JR, Egloff AM.Tumor epidermal growth factor receptor (EGFR) and
EGFR PY1068 are independent prognostic indicators for head and neck
squamous cell carcinoma. Clin Cancer Res. 2012 Apr 15;18(8):2278-89
19. Mburu YK, Egloff AM, Walker WH, Wang L, Seethala RR, van Waes C,
Ferris RL. Chemokine receptor 7 (CCR7) gene expression is regulated by
NF-κB and activator protein 1 (AP1) in metastatic squamous cell
carcinoma of head and neck (SCCHN). J Biol Chem. 2012 Jan
27;287(5):3581-90.
20. Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF 4th,
Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL. Serum
biomarkers as potential predictors of antitumor activity of cetuximab-
containing therapy for locally advanced head and neck cancer. Oral Oncol.
2011 Oct;47(10):961-6
21. Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ,
Stoller RG, Grandis JR, Egloff AM. Phase I and pharmacokinetic study of
dasatinib and cetuximab in patients with advanced solid malignancies.
Invest New Drugs. 2011 Sep 1

5. 22. Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver
DT, D'Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR.
XPF expression correlates with clinical outcome in squamous cell
carcinoma of the head and neck. Clin Cancer Res. 2011 Aug
15;17(16):5513-22.
23. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko
A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E,
Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger
MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld
JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC,
Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel
SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis
JR. The Mutational Landscape of Head and Neck Squamous Cell
Carcinoma. Science 26 August 2011: Vol. 333 no. 6046 pp. 1157-1160.
24. Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter
BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis
JR, Johnson JT, Ferris RL. Induction docetaxel, cisplatin, and cetuximab
followed by concurrent radiotherapy, cisplatin, and cetuximab and
maintenance cetuximab in patients with locally advanced head and neck
cancer. J Clin Oncol. 2010 Dec 20; 28(36):5294-300.
25. Kropf PL, L Wang, Y Zang, RL Redner and DE Johnson. Dasatinib
promotes ATRA-induced differentation of AML cells. Leukemia
24(3):663-665, 2010.
26. JE Jones, L Wang, PL Kropf, R Duan, DE Johnson. Src family kinase
gene targets during myeloid differentiation: identification of the EGR-1
gene as a direct target. Leukemia. 2009 October; 23(10): 1933–1935.
27. Kim SI, Kwak JH, Wang L, Choi ME. Protein phosphatase 2A is a
negative regulator of transforming growth factor-beta 1-induced TAK1 in
mesangial cells. J Biol Chem. 2008 Apr 18; 283(16):10753-10763.
28. Wang L, Lee JY, Kwak JH, He Y, Kim SI, Choi ME.Protective effects of
low-dose carbon monoxide against renal fibrosis induced by unilateral
ureteral obstruction. Am J Physiol Renal Physol. 2008 Mar; 294(3):F508-
517.

6. 29. Kim SI, Kwak JH, Zachariah M, He Y, Wang L, Choi ME TGF-beta -
activated kinase 1 and TAK1-binding protein 1 cooperate to mediate TGF-
beta1-induced MKK3-p38 MAPK activation and stimulation of type I
collagen. Am J Physiol Renal Physiol. 2007 May; 292(5):F1471- 1478.
30. Wang L, Kwak JH, Kim SI, He Y, Choi ME. Transforming growth
factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-
activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated
protein kinase-dependent pathway in murine mesangial cells. J Biol Chem.
2004 Aug 6; 279 (32):33213-33219.
31. Wang L, Ma R, Flavell RA, Choi ME.Requirement of Mitogen-activated
Protein Kinase Kinase 3 (MKK3) for Activation of p38 α and p38 δ
MAPK isoforms by TGF-ß1 in murine mesangial cells. J Biol Chem 2002
Dec 6; 277 (49), 47257-47262.
32. Lin Wang, Mi Xiong, Dongyuan Che, et al. Effect of hypoxia on
proliferation and differentiation of the pulmonary vascular pericytes.
Chinese Journary of Tuberculosis and Respiratory Disease, 1999,
22(3):176-178.
PRESENTATIONS
Presentations:
1. Mitogen-Activated Protein Kinase Kinase 3 (MKK3) Mediates Activation of p38
MAPK by TGF-β1 in Mesangial Cells. (Poster), ASN (America Society of Nephrology)
conference, San Francisco, California, Oct, 2001
2. Selective Activation of p38 MAPK Isoforms p38 α and p38δ by TGF-β1 Is Mediated
Via Mitogen-Activated Protein Kinase Kinase (MKK3) in Mouse Mesangial Cells. (Oral),
ASN (America Society of Nephrology) conference, Philadelphia, Pennsylvania, Nov, 2002

7. 3. Mitogen-Activated Protein Kinase Kinase 3 (MKK3)-p38MAPK (p38 α and p38δ)
Pathway Mediates TGF-β1 induced –Expression of Vascular Endothelial Growth Factor
(VEGF) in Mouse Mesangial Cells. (Poster), ASN (America Society of Nephrology)
conference, San Diego, Nov, 2003
4. Protective Effects of Carbon Monoxide (CO) To Inhibit Renal Fibrosis in Obstructive
Nephropathy. (Poster), ASN (America Society of Nephrology) conference, St. Louis,
Missouri, Nov, 2004
5. Protective effects of low-dose carbon monoxide (CO) against renal fibrosis induced by
unilateral ureteral obstruction. (Oral), Research Day, Department of Medicine, University of
Pittsburgh School of Medicine, May, 2006
6. Carbon monoxide (CO) inhibits profibrotic effects of TGF-ß1 in renal tubular epithelial
cells, via the MKK3-p38β MAPK pathway. (Poster), American Society of Nephrology (ASN)
conference. Philadelphia, Pennsylvania, Nov , 2006